Rinsho Ketsueki
Online ISSN : 1882-0824
Print ISSN : 0485-1439
ISSN-L : 0485-1439
Volume 54, Issue 8
Displaying 1-20 of 20 articles from this issue
Picture in Clinical Hematology
Feature Articles: current topics in multiple myeloma 2013
Feature Articles: pediatric hematology for the non-pediatric hematologists
The 73rd Annual Meeting of the Japanese Society of Hematology
Special Award Received Lecture
Case Reports
  • Yoshikazu UTSU, Nobuyuki AOTSUKA, Shinichi MASUDA, Yasuhiro MATSUURA, ...
    2013 Volume 54 Issue 8 Pages 759-763
    Published: 2013
    Released on J-STAGE: September 05, 2013
    JOURNAL RESTRICTED ACCESS
    A 51-year-old woman diagnosed as having left breast cancer with axillary lymph node and liver metastases seven years earlier was seen in our office because of severe pancytopenia. She had received chemotherapy including several cycles of doxorubicin plus cyclophosphamide and docetaxel followed by hormone therapy containing leuprorelin and tamoxifen over four years. For management of bone pain due to metastasis, she had also undergone stereotaxic radiation therapy of the neck one and a half years earlier and unsealed internal radiation therapy with 89Sr injection five months prior to the current presentation, Subsequently, myelosuppression progressively worsened and she finally required a blood transfusion. Although bone marrow examination showed severe hypoplasia, but neither blastic nor dysplastic, a test for PML-RARA fluorescence in situ hybridization was positive. After administration of all-trans retinoic acid, hematogenesis improved within three weeks. Neither disseminated intravascular coagulation nor retinoic acid syndrome was observed during the course of her illness. This is the first report describing acute promyelocytic leukemia after administration of 89Sr, to our knowledge, and with an atypical onset and progression. As the number of cancer survivors increases due to improvements in medical intervention, clinicians must take more notice of special characteristics of therapy-related leukemia modified by previous treatments.
    Download PDF (1334K)
  • Takuya SUYAMA, Naoshi OBARA, Koji KAWAI, Kenji YAMADA, Manabu KUSAKABE ...
    2013 Volume 54 Issue 8 Pages 764-768
    Published: 2013
    Released on J-STAGE: September 05, 2013
    JOURNAL RESTRICTED ACCESS
    This report describes a 30-year-old man with a testicular germ cell tumor, which later developed into acute myeloid leukemia (AML) with a common chromosomal abnormality. Testicular germ cell tumors had developed at the age of 26. He was successfully treated with surgery followed by chemotherapy.
    Four years after the onset of the germ cell tumor, he developed pancytopenia with elevated serum LDH. More than 95% of the bone marrow was occupied by blastic cells. These cells were CD13+, CD34+ but CD45- and MPO-. Amplification of the short arm of chromosome 12 was recognized by fluorescence in situ hybridization using the blastic cells in the bone marrow and the previous testicular tumor specimen. Because testicular germ cell tumor recurrence and other malignant tumors could be ruled out pathologically, he was diagnosed as having AML.
    Allogeneic stem cell transplantation from a HLA-matched sibling donor was performed after chemotherapy. As of 19 months after the transplantation, recurrence of neither AML nor testicular tumors has been observed. Because the same genetic abnormality was observed in the testicular germ cell tumor and AML in this case, the possibility of AML having a common origin with the testicular germ cell tumor is indicated.
    Download PDF (2170K)
A Short Report
  • Takahiro TSUJI, Keiko MORIKAWA, Taichi HIRANO, Hiroshi YAMASAKI, Hiroy ...
    2013 Volume 54 Issue 8 Pages 769-771
    Published: 2013
    Released on J-STAGE: September 05, 2013
    JOURNAL RESTRICTED ACCESS
    An 82-year-old female with a history of aortic dissection was admitted to our hospital for evaluation of thrombocytopenia and a bleeding tendency. Blood coagulation test data demonstrated that the patient had disseminated intravascular coagulation (DIC) secondary to aortic dissection. We initiated anti-fibrinolytic therapy with tranexamic acid. After this anti-fibrinolytic therapy, thrombocytopenia and the levels of fibrinogen and fibrinogen degradation products improved. In addition, we reviewed 7 other patients who were treated with tranexamic acid for DIC associated with aortic dissection. Anti-fibrinolytic therapy with tranexamic acid is effective for treating DIC secondary to aortic dissection.
    Download PDF (924K)
Introduce My Article
feedback
Top